Introduction
Although a decrease is seen in the mortality rate with the widespread of
primary percutaneous coronary intervention (p-PCI) in patients with
ST-elevation myocardial infarction (STEMI), there is still a high rate
of mortality1. The rapid and successful
revascularization of the infarct-related artery (IRA) has proven to be
the most effective treatment option in patients with STEMI and improves
clinical outcomes. IRA patency before p-PCI cause the short duration of
ischemia in STEMI patients, thus decreasing complications such as
infarction-related heart failure, cardiogenic shock and mortality, and
high procedure success2.
The use of inflammatory biomarkers has been increasing in the diagnosis
and screening of atherosclerotic heart disease (AHD)3.
Among the most frequently used biomarkers for this purpose, C-reactive
protein (CRP) and albumin are known to have a strong association with
individual AHD formation and presentation forms.4,5C-reactive protein/Albumin ratio (CAR) reflects the stability of albumin
and CRP levels in the body. It has been shown to reflect the
inflammatory status and prognosis better than the hs-CRP or albumin
alone in critical patients, acute medical conditions, and cancer
patients6-9.
Detection of IRA patency in p-PCI in patients with STEMI provides
predicting mortality and morbidity rates of the
patients10. Therefore, in the present study, it was
aimed to investigate the relationship between IRA patency before p-PCI
and CAR in patients with STEMI.